Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shortfall In Rebates Could Stymie UK Generics Industry’s Call For Exemptions Under New Pricing Scheme

Executive Summary

The UK’s generics and biosimilars industry body, the BGMA, has set out what it wants from the new drug pricing scheme due to start up in January 2024. But a key request – exempting some branded generics and biosimilars from rebates - would leave a hole in the government’s finances.

You may also be interested in...



UK Generics Body Denied In Bid To Negotiate Over VPAS Rebate Scheme

UK generics and biosimilars industry association the BGMA has been denied in its bid to overturn a government decision to exclude it from formal negotiations over the VPAS rebate scheme.

UK Generics Body Sets Out Suggestions For Overhaul Of Voluntary Price Scheme

Claiming that the UK’s VPAS rebate scheme is “out of control,” the generics and biosimilars industry association, the BGMA, has set out a series of suggestions to improve the mechanism, as it continues to battle for formal involvement in negotiations with the government.

Legal Challenge Could Put UK Drug Pricing Deal At Risk

The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel